Comparison of Health Services Use Associated with Ziprasidone and Olanzapine among Schizophrenia and Bipolar Disorder Patients in the USA

[1] Colombo GL(2008)An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia Neuropsychiatr Dis Treat 4 967-552

[2] Caruggi M(2007)Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch Gen Psychiatry 64 543-7

[3] Di Matteo S(2006)The costs of schizophrenia J Clin Psychiatry 68 4-1290

[4] Rossi A(2003)Insurance expenditures on bipolar disorder: clinical and parity implications Am J Psychiatry 160 1286-83

[5] Merikangas KR(2011)An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009 J Affect Disord 129 79-179

[6] Akiskal HS(2004)Atypical antipsychotics as first-line treatments for schizophrenia Dis Manag Health Outcomes 12 169-11

[7] Angst J(2004)The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania J Clin Psychiatry 66 5-687

[8] Greenberg PE(2013)Diffusion of antipsychotics in the US and French markets, 1998–2008 Psychiatr Serv 64 680-76

[9] Hirschfeld RM(2006)Patient-and facility-level factors associated with diffusion of a new antipsychotic in the VA health system Psychiatr Serv 57 70-506

[10] Petukhova M(2008)Special section on implications of CATIE: what CATIE found: results from the schizophrenia trial Psychiatr Serv 59 500-43

[1] Colombo GL(2008)An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia Neuropsychiatr Dis Treat 4 967-552

[2] Caruggi M(2007)Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch Gen Psychiatry 64 543-7

[3] Di Matteo S(2006)The costs of schizophrenia J Clin Psychiatry 68 4-1290

[4] Rossi A(2003)Insurance expenditures on bipolar disorder: clinical and parity implications Am J Psychiatry 160 1286-83

[5] Merikangas KR(2011)An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009 J Affect Disord 129 79-179

[6] Akiskal HS(2004)Atypical antipsychotics as first-line treatments for schizophrenia Dis Manag Health Outcomes 12 169-11

[7] Angst J(2004)The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania J Clin Psychiatry 66 5-687

[8] Greenberg PE(2013)Diffusion of antipsychotics in the US and French markets, 1998–2008 Psychiatr Serv 64 680-76

[9] Hirschfeld RM(2006)Patient-and facility-level factors associated with diffusion of a new antipsychotic in the VA health system Psychiatr Serv 57 70-506

[10] Petukhova M(2008)Special section on implications of CATIE: what CATIE found: results from the schizophrenia trial Psychiatr Serv 59 500-43